SLN

Silence Therapeutics (SLN)

Silence Therapeutics PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SLN
FechaHoraFuenteTítuloSímboloCompañía
24/04/202508:28Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:SLNSilence Therapeutics PLC
24/04/202506:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNSilence Therapeutics PLC
27/02/202516:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNSilence Therapeutics PLC
27/02/202515:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNSilence Therapeutics PLC
27/02/202506:30Business WireSilence Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateNASDAQ:SLNSilence Therapeutics PLC
13/02/202507:00Business WireSilence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025NASDAQ:SLNSilence Therapeutics PLC
11/02/202517:41Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SLNSilence Therapeutics PLC
02/01/202515:43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLNSilence Therapeutics PLC
09/12/202407:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
09/12/202406:30Business WireSilence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual MeetingNASDAQ:SLNSilence Therapeutics PLC
26/11/202407:00Business WireSilence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
18/11/202413:30Business WireSilence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual MeetingNASDAQ:SLNSilence Therapeutics PLC
14/11/202412:13Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SLNSilence Therapeutics PLC
14/11/202407:00Business WireSilence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/11/202407:00Business WireSilence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
27/08/202407:00Business WireSilence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesNASDAQ:SLNSilence Therapeutics PLC
15/08/202406:30Business WireSilence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
27/06/202406:30Business WireSilence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera PatientsNASDAQ:SLNSilence Therapeutics PLC
24/06/202407:30Business WireSilence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma CollaborationNASDAQ:SLNSilence Therapeutics PLC
20/06/202406:30Business WireSilence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
30/05/202407:30Business WireSilence Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
16/05/202407:30Business WireSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressNASDAQ:SLNSilence Therapeutics PLC
14/05/202415:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SLNSilence Therapeutics PLC
08/05/202416:14Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:SLNSilence Therapeutics PLC
30/04/202407:30Business WireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:SLNSilence Therapeutics PLC
29/04/202407:30Business WireSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsNASDAQ:SLNSilence Therapeutics PLC
08/04/202410:48Business WireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
13/03/202406:05Business WireSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/03/202406:03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:SLNSilence Therapeutics PLC
13/03/202406:00Business WireSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:SLN

Su Consulta Reciente

Delayed Upgrade Clock